SCHEMBL19726992

SCHEMBL19726992

C#CCCC(=O)NCCOCCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
EPHX2 P34913 2/20 0.39
CASP2 P42575 1/20 0.37
TSHR P16473 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CNR1 P21554 1/20 0.35
NAAA Q02083 1/20 0.35
SELP P16109 1/20 0.35
FAAH O00519 3/20 0.34
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA4 P22748 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34
LPAR1 Q92633 2/20 0.34
LPAR2 Q9HBW0 2/20 0.34
ENPP2 Q13822 1/20 0.34
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19727004 0.98 L3MBTL1 (0.40) L3MBTL1EPHX2CASP2TSHRMEN1
SCHEMBL20393655 0.88 L3MBTL1 (0.44) L3MBTL1EPHX2TSHRCNR1SELP
SCHEMBL19727002 0.85 TSHR (0.35) L3MBTL1TSHRMEN1KMT2ACA12
SCHEMBL19733751 0.83 FAAH (0.34) L3MBTL1TSHRMEN1KMT2AFAAH
SCHEMBL19821398 0.83 CA2 (0.37) L3MBTL1EPHX2TSHRMEN1KMT2A
SCHEMBL19733753 0.83 TSHR (0.40) L3MBTL1EPHX2TSHRMEN1KMT2A
SCHEMBL19727009 0.83 CA2 (0.34) L3MBTL1TSHRMEN1KMT2ACA12
SCHEMBL19726993 0.83 CA2 (0.37) L3MBTL1TSHRMEN1KMT2ACA12
SCHEMBL3768113 0.83 CA2 (0.37) L3MBTL1TSHRMEN1KMT2ACA12
SCHEMBL19369940 0.83 MEN1 (0.37) L3MBTL1TSHRMEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287030-A1 Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions THE GENERAL HOSPITAL CORPORATION 2023-09-14 US disclosed
US-20170362266-A1 Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions THE GENERAL HOSPITAL CORPORATION 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362266-A1 Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions GALNT14, NEU4, CSGALNACT1 L3MBTL1 2797/4885EPHX2 2951/4885CASP2 4453/4885
US-20230287030-A1 Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions GALNT14, NEU4, CSGALNACT1 L3MBTL1 2797/4885EPHX2 2951/4885CASP2 4453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.